160 related articles for article (PubMed ID: 10749583)
1. Detection of TNFalpha expression in the bone marrow and determination of TNFalpha production of peripheral blood mononuclear cells in myelodysplastic syndrome.
Molnár L; Berki T; Hussain A; Németh P; Losonczy H
Pathol Oncol Res; 2000; 6(1):18-23. PubMed ID: 10749583
[TBL] [Abstract][Full Text] [Related]
2. [[The role of TNF-alpha in myelodysplastic syndrome: immunoserologic and immunohistochemical studies] ].
Molnár L; Berki T; Hussain A; Németh P; Losonczy H
Orv Hetil; 2000 Aug; 141(33):1807-11. PubMed ID: 10979309
[TBL] [Abstract][Full Text] [Related]
3. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes.
Sawanobori M; Yamaguchi S; Hasegawa M; Inoue M; Suzuki K; Kamiyama R; Hirokawa K; Kitagawa M
Leuk Res; 2003 Jul; 27(7):583-91. PubMed ID: 12681357
[TBL] [Abstract][Full Text] [Related]
4. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
Wimazal F; Krauth MT; Vales A; Böhm A; Agis H; Sonneck K; Aichberger KJ; Mayerhofer M; Simonitsch-Klupp I; Müllauer L; Sperr WR; Valent P
Leuk Lymphoma; 2006 Mar; 47(3):451-60. PubMed ID: 16396768
[TBL] [Abstract][Full Text] [Related]
6. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blood chromosome aberrations in MDS.
White AD; Jacobs A
Cancer Genet Cytogenet; 1992 Apr; 59(2):167-72. PubMed ID: 1581882
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-specific reduction in the expression of granulocyte--macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes.
Shikama Y; Shichishima T; Ohto H; Jubinsky PT; Maruyama Y
Br J Haematol; 2000 Dec; 111(3):863-72. PubMed ID: 11122148
[TBL] [Abstract][Full Text] [Related]
9. Increased serum interleukin 6 levels in patients with myelodysplastic syndromes.
Herold M; Schmalzl F; Zwierzina H
Leuk Res; 1992; 16(6-7):585-8. PubMed ID: 1635376
[TBL] [Abstract][Full Text] [Related]
10. Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.
Gelsi-Boyer V; Cervera N; Bertucci F; Brecqueville M; Finetti P; Murati A; Arnoulet C; Mozziconacci MJ; Mills KI; Cross NC; Vey N; Birnbaum D
Haematologica; 2013 Apr; 98(4):576-83. PubMed ID: 23065512
[TBL] [Abstract][Full Text] [Related]
11. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
[TBL] [Abstract][Full Text] [Related]
12. Chromosome analyses in patients with myelodysplastic syndromes: correlation with bone marrow histopathology and prognostic significance.
Werner M; Maschek H; Kaloutsi V; Choritz H; Georgii A
Virchows Arch A Pathol Anat Histopathol; 1992; 421(1):47-52. PubMed ID: 1636249
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide for the treatment of patients with myelodysplastic syndromes.
Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N
Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256
[TBL] [Abstract][Full Text] [Related]
14. [Serum proteomics in patients with RAEB myelodysplastic syndromes].
Zhong LY; Liu TH; Li YQ; Geng SX; Lu ZS; Weng JY; Wu SJ; Luo CW; Du X
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Sep; 29(9):1799-801. PubMed ID: 19778794
[TBL] [Abstract][Full Text] [Related]
15. Global gene expression profile in myelodysplastic syndromes using SAGE.
Mendiburu CF; Silva WA; Ricci O; Bonini-Domingos CR; Fett-Conte AC
Genet Mol Res; 2008; 7(4):1245-50. PubMed ID: 19065759
[TBL] [Abstract][Full Text] [Related]
16. No concomitant occurrence of the N-ras and p53 gene mutations in myelodysplastic syndromes.
Mitani K; Hangaishi A; Imamura N; Miyagawa K; Ogawa S; Kanda Y; Yazaki Y; Hirai H
Leukemia; 1997 Jun; 11(6):863-5. PubMed ID: 9177441
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia.
Koike M; Ishiyama T; Tomoyasu S; Tsuruoka N
Leuk Res; 1995 Sep; 19(9):639-44. PubMed ID: 7564474
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome.
Pülhorn H; Herrmann M; Harms H; Jung A; Baumann I
Histopathology; 2012 Aug; 61(2):200-11. PubMed ID: 22690734
[TBL] [Abstract][Full Text] [Related]
19. Endogenous serum thrombopoietin concentrations in patients with myelodysplastic syndromes.
Zwierzina H; Rollinger-Holzinger I; Nuessler V; Herold M; Meng YG
Leukemia; 1998 Jan; 12(1):59-64. PubMed ID: 9436921
[TBL] [Abstract][Full Text] [Related]
20. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases.
Bourgeois E; Caulier MT; Rose C; Dupriez B; Bauters F; Fenaux P
Leukemia; 2001 Jun; 15(6):950-3. PubMed ID: 11417482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
